India's Natco Eyes Generic For Celgene's Mega Brand Revlimid; Will REMS Scuttle The Move?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Although U.S.-headquartered Celgene succeeded last year in preventing India's Dr. Reddy's Labs from conducting bioequivalence studies on its fast-growing multiple myeloma drug Revlimid (lenalidomide) - due to risk management and restricted distribution issues - it may have a much harder fight on its hands now